Podocyte injury is a significant contributor to proteinuria and glomerulosclerosis. Recent studies have shown a renoprotective effect of erythropoietin (EPO) during ischemic kidney disease. In this study, we examine mechanisms by which a long acting recombinant EPO analog, darbepoetin, may confer renoprotection in the puromycin aminonucleoside-induced model of nephrotic syndrome. Darbepoetin decreased the proteinuria of rats treated with puromycin. This protective effect was correlated with the immunohistochemical disappearance of the podocyte injury markers desmin and the immune costimulator molecule B7.1 with the reappearance of nephrin expression in the slit diaphragm. Podocyte foot process retraction and effacement along with actin filament rearrangement, determined by electron microscopy, were all reversed by darbepoetin treatment. The protective effects were confirmed in puromycin-induced nephrotic rats that had been hemodiluted to normal hematocrit levels. Furthermore, puromycin treatment of rat podocytes in culture caused actin cytoskeletal reorganization along with deranged nephrin distribution. All these effects in vitro were reversed by darbepoetin. Our study demonstrates that darbepoetin treatment ameliorates podocyte injury and decreases proteinuria by a direct effect on podocytes. This may be accomplished by maintenance of the actin cytoskeleton and nephrin expression. The terminally differentiated podocyte, also called glomerular visceral epithelial cell, is a highly specialized cell. The clinical signature of podocyte injury is proteinuria, and podocyte loss in association with the inability to replace those lost because of a lack of proliferation results in glomerulosclerosis.
The terminally differentiated podocyte, also called glomerular visceral epithelial cell, is a highly specialized cell. The clinical signature of podocyte injury is proteinuria, and podocyte loss in association with the inability to replace those lost because of a lack of proliferation results in glomerulosclerosis. 1, 2 The characteristic morphological changes observed during the development of proteinuria occur in podocytes. Foot process effacement is closely correlated with the development of proteinuria. 3, 4 These shape changes in the podocytes are also associated with rearrangement of actin cytoskeleton. 5, 6 The expression of nephrin, which is a major component of slit diaphragms, also decreases in a variety of disease conditions characterized by proteinuria. [7] [8] [9] Anemia is a common complication of chronic kidney disease. Development of recombinant erythropoietin (EPO) as a therapeutic reagent is one of the major advances in the management of patients with chronic kidney failure over the past several decades. 10 In addition to correction of anemia, accumulating evidence indicates that EPO has effects outside of the hematopoietic system and serves as a novel cytoprotective agent in both neuronal and vascular systems. 11, 12 Previous studies focused on a renoprotective effect of EPO in ischemic kidney diseases (reviewed by Sharples and Yaqoob 13 Chatterjee 14 )
. Important mechanisms of renoprotection by EPO include antiapoptotic effects and recruitment of endothelial precursor cells. 15, 16 However, demonstration of cytoprotection of EPO in a variety of organs stimulated us to study a therapeutic potential of EPO in podocyte injury. We employed the long-acting recombinant human EPO analogue, darbepoetin alpha, in a model of nephrotic syndrome induced by puromycin aminonucleoside (PAN). Darbopoietin is an analogue of recombinant human EPO with increased glycosylation that stimulates erythropoiesis via the same mechanism as the native hormone and has a greater in vivo metabolic stability. Injection of PAN causes podocyte injury, for example, actin cytoskeletal disorganization, reduced expression of molecular components of slit diaphragm such as nephrin, and foot process effacement, leading to induction of a well-described model of proteinuria.
RESULTS

Darbepoetin ameliorates proteinuria in PAN
PAN induced massive proteinuria on day 7, which was significantly suppressed by darbepoietin (Table 1) . Darbepoetin treatment at this dose increased the levels of hematocrit and hemoglobin (Hb), whereas it did not induce significant changes in blood urea nitrogen levels.
Histological and immunohistochemical analysis revealed protection of podocytes by darbepoetin. Periodic acid-Schiff staining of kidney samples from experimental animals showed no abnormal findings in glomeruli, whereas the tubulointerstitial compartment showed tubular injury and inflammation, reflecting massive proteinuria (data not shown). Immunohistochemical studies showed upregulation of desmin, a marker of podocyte injury, in PAN rats ( Figure  1a-c) . In the normal kidney, anti-desmin antibody weakly reacted with the mesangial cells, whereas staining in the podocytes was negative. In PAN rats, conspicuously enhanced staining for desmin was seen in the podocytes, whereas darbepoetin treatment resulted in a decrease in desmin expression by the podocytes. Expression of B7-1, another indicator of podocyte damage, was also upregulated in PAN animals (Figure 2a-c) . Darbepoetin treatment also ameliorated B7-1 expression in podocytes. Immunostaining of a podocyte-associated protein, nephrin, yielded an epitheliallike pattern in glomeruli, whereas the innermost glomerular tuft areas remained negative, in normal rats. Induction of PAN resulted in a less intense reactivity at the epithelial aspect, whereas darbepoetin treatment recovered nephrin staining in podocytes (Figure 3a-c) . Dramatic mitigation of the abnormal staining profile of desmin and nephrin in podocytes was confirmed by semiquantitative analyses (Figure 1d, 3d) .
Electron microscopic analysis showed swollen podocytes in PAN. The foot processes of podocytes retracted and effaced (Figure 4 ), resulting in displacement and disruption of the specialized slit diaphragms that span the filtration slits between foot processes. Foot process fusion was often associated with detachment from the underlying glomerular basement membrane. These are the characteristic ultrastructural changes observed during the development of nephrotic syndrome. These alterations were highly diffuse and were closely associated with dramatic rearrangements of the actin filaments in foot processes. These changes were ameliorated in darbepoetin-treated rats.
Darbepoetin suppresses derangements of actin and nephrin in cultured podocytes
In order to elucidate a mechanism of darbepoetin-mediated improvement in the glomerular barrier function, we employed cultured rat podocytes. F-actin staining revealed a characteristic flattened phenotype with numerous cell processes and prominent central actin stress fibers in cultured podocytes before treatment (Figure 5c ). Treatment of podocytes with PAN resulted in a progressive retraction of processes, disruption of the actin stress fibers, and subsequent detachment of some podocytes from the underlying substrate, whereas darbepoetin suppressed the actin cytoskeletal reorganization evoked by PAN (Figure 5a and b) . Protection against actin cytoskeletal reorganization by darbepoetin treatment tended to be observed in a dose-dependent manner ( Figure 6 ). PAN treatment also induced a reduction of nephrin expression in cultured podocytes, however, darbepoetin treatment markedly restored ( Figure 7 ). Moreover, in order to elucidate the possibility that protective effects of darbepoetin had been through receptor tyrosine kinases (RTKs), we examine whether the beneficial effects could be perturbed by RTK inhibitors for example PD153035 for epidermal growth factor o r i g i n a l a r t i c l e receptor and SU1498 for vascular endothelial growth factor receptor. As shown in Figure 8 , actin cytoskeletal reorganization was protected by darbepoetin treatment even in the presence of the RTK inhibitors.
Darbepoetin ameliorates proteinuria in PAN rats with hemodilution
In order to evaluate a possible contribution of polycythemia to a beneficial effect by darbepoetin, we performed weekly hemodilution in darbepoietin-treated rats. As shown in Table 2 , hemodilution kept the levels of hematocrit and Hb of darbepoietin-treated animals within the normal range. However, massive proteinuria was significantly suppressed by darbepoietin on days 7 and 14 even in these hemodiluted rats, whereas it did not induce significant changes in blood urea nitrogen levels (29.3 interquartile range (26.6-31.1) versus 24.5 interquartile range (22.4-29.5) mg/dl, on day 14).
EPO-R expression in rat podocytes
To confirm the localization of EPO receptor (EPO-R) in rat glomeruli, we first performed immunohistochemical analysis in rat kidney tissues. We observed EPO-R expression in podocytes as well as in tubular cells (Figure 9a ). In addition, reverse transcriptase-polymerase chain reaction (RT-PCR) and immunoblot analysis also demonstrated EPO-R expression in cultured rat podocytes (Figure 9c and d). Both data indicated the expression of EPO-R in rat podocytes.
TUNEL staining
To investigate whether the protective effect of darbepoetin in the podocytes was due to amelioration of apoptosis in addition to the cytoskeletal protection, we performed terminal deoxynucleotidyl transferase (TdT)-mediated deoxyuridin triphosphate (dUTP) nick end labeling (TUNEL) staining in both kidneys of the experimental rats and cultured podocytes. As shown in Figure 10 , no positive signals were present in the glomeruli of vehicle-and darbepoetin-treated rats. Studies utilizing cultured podocytes also demonstrated no significant difference between vehicle-and darbepoetintreated groups. Taken together, these results suggest that podocyte apoptosis is unlikely to contribute to the beneficial effects by darbepoietin in our experimental conditions.
DISCUSSION
The question addressed by the present study was whether darbepoetin has a direct action on podocytes resulting in protection from and/or amelioration of injury. Our study demonstrated that darbepoetin reduced urinary protein excretion in PAN rats by protection of podocytes. Protection of podocytes by darbepoietin was demonstrated by electron microscopic analysis as well as two established podocyte injury markers, that is desmin 17 and B7-1.
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Although it is plausible to speculate that an increase in oxygen-carrying capacity might improve structures and functions of podocytes, it is an unlikely mechanism in PAN. Injury of podocytes in this model is mediated by oxidative stress and direct insults induced by PAN, 19, 20 but no previous reports suggested a role of hypoxia in podocyte injury of PAN. In order to rule out a possible contribution of an increase in hematocrit, we conducted hemodilution in darbepoetin-treated PAN rats. We observed equivalent protective effects of darbepoetin even when hematocrit between vehicle-and darbepoetin-treated rats was kept at the same levels.
To elucidate the mechanisms of protective action of EPO in PAN, we performed in vitro study using immortalized rat podocytes. The major finding in our in vitro study was that EPO protected the disruption of actin cytoskeleton and the reduction of nephrin caused by PAN.
A well-developed actin cytoskeletal structure plays a critical role in the maintenance of podocyte foot process architecture and filtration barrier function. Pathogenic stimuli such as PAN cause actin cytoskeletal reorganization. 5, 21 Nephrin, a critical component of the slit diaphragm for maintaining the barrier function, 22 is coupled to the podocyte's actin cytoskeleton, and derangement of the actin cytoskeleton is proposed to be the common pathway leading to foot process effacement in podocytes. 23 Previous reports showed a decrease in nephrin expression in PAN. 24, 25 Mounting evidence has demonstrated that PAN induces actin cytoskeleton reorganization, which can lead to structural change of podocytes and the leak of protein through slit diaphragm. However, the precise mechanisms of this deleterious effect have remained to be fully understood. Previous reports showed that reagents such as fluvastatin, dexamethasone, and an inhibitor of p38 MAPK have protective effects on actin disruption induced by PAN. [26] [27] [28] In the current study, we newly demonstrated that the longacting recombinant human EPO analogue, darbepoetin alpha, prevented the change of actin cytoskeleton and the decrease of nephrin protein, whereas RTK inhibitors did not alter the protective effects of darbepoetin in vitro, suggesting that the beneficial effects observed in vivo may be due to the prevention of these changes through the direct action of EPO on podocytes.
Previous immunohistochemical and in situ hybridization studies demonstrated expression of EPO-R in podocytes in addition to tubular epithelial cells and glomerular endocapillary cells. 29 Our immunohistochemical, reverse transcriptase-PCR and immunoblot analyses also showed the expression of EPO-R in podocyte. EPO and EPO-R prevent apoptosis and cellular inflammation through a series of pathways that originate with the binding of EPO to the EPO-R to activate Janus-tyrosine kinase 2, phosphoinositide 3 kinase, and protein kinase B (Akt). 30, 31 It is noteworthy that several reports showed the direct interaction of Akt and actin. Two groups revealed that the major protein observed in Akt co-immunoprecipitates was the actin cytoskeleton and growth factor such as platelet-derived growth factor triggers an increase in the amount of Akt association with the actin cytoskeleton. 32, 33 In chicken embryo fibroblast, phosphoinositide 3 kinase activation via Akt is sufficient for actin filament remodeling. 34 Meanwhile, it was also reported that Akt activation diminished cellular apoptosis in some types of kidney cells, that is glomerular endothelial cells and epithelial cells. 15 However, our TUNEL-staining studies suggested that anti-apoptosis effects of Akt were not involved in the protective effects of darbepoetin on podocytes in our experimental conditions. Although direct interaction of Akt and actin may be involved in the beneficial mechanism of EPO in podocytes, further elucidation of the EPO-mediated signal transduction pathway in podocytes is necessary.
The first evidence of non-hematopoietic effect by EPO was shown in the study demonstrating that infusion of EPO into the lateral ventricles of gerbils prevented ischemia-induced learning disability and rescued hippocampal CA1 neurons from lethal ischemic damage. 35 Subsequent studies showed beneficial effects of EPO in the brain, heart, and kidney. 36 Recently developed EPO without hematopoiesis, carbamylated EPO, was effective without an increase in Hb levels in a model of cerebral infarction 37 as well as myocardial infarction. 38 Previous studies showed reduction of proteinuria by EPO and darbepoetin in the remnant kidney model. 15, 39 Anti-proteinuric effects of EPO and darbepoetin in these studies may be, at least in part, attributed to direct protection of podocytes.
Some clinical studies showed renoprotective effects of EPO in human chronic kidney disease patients. Kuriyama et al. 40 were the first to raise the possibility that EPO therapy might actually delay progression of kidney disease. Other studies also found stabilization of renal function by EPO treatment. [41] [42] [43] [44] Although the beneficial effects observed in these studies can be attributed to improvement of chronic hypoxia in the tubulointerstitial compartment, 45 our current study suggested that direct cytoprotection of EPO on intrinsic renal cells may also participate.
The dose of darbepoetin we used in this study was relatively more than those employed clinically in human chronic kidney disease patients (45 mg every-other-week per person). 46 Our results indicated that a supraphysiological dose of EPO was necessary in order to see a protective effect on podocytes, which may limit the actual clinical application. However, this dose was comparable to those used in previous experimental studies. 47, 48 Larger doses of darbepoetin has also been used in some clinical situations such as postmyocardial infarction. 49 Calculation utilizing the suggested conversion index (epoietin alfa dose/200 ¼ darbepoetin dose) also suggested that the dose of darbepoetin we employed in this study was comparable to those of EPO used in many previous studies. 14 In conclusion, we demonstrated that darbepoietin protected the kidney against PAN. Darbepoietin treatment ameliorated podocyte injury and reduced proteinuria. In vitro experiments utilizing rat podocytes showed that darbepoietin protected the disruption of actin cytoskeleton and the reduction of nephrin. Our studies suggested that darbepoietin may provide direct protection on podocytes, the major culprit accounting for proteinuria.
MATERIALS AND METHODS Chemicals PAN was purchased from Sigma (St Louis, MO, USA). Alexa488 phalloidin was purchased from Invitrogen (Eugene, OR, USA). The inhibitors, PD153035, and SU1498 were purchased from Calbiochem (San Diego, CA, USA).
Animal experimental design
Male Wistar rats that weighed 150-180 g were purchased from Nihon Seibutsu Zairyo Center (Tokyo, Japan). All animal procedures conducted were in accordance with the guidelines for the care and use of laboratory animals approved by University of Tokyo School of Medicine. Rats were divided into PAN and darbepoetintreated PAN groups (n ¼ 6 for each). PAN was induced by a single intravenous injection of PAN (50 mg/kg body weight). Darbepoetin (30 mg/kg) was administered subcutaneously 4 h before induction of the disease.
On day 7, urine was collected using a metabolic cage, followed by killing under ether anesthesia. Blood urea nitrogen, hematocrit, and Hb were measured utilizing i-STAT (Abbott, East Windsor, NJ, USA).
For the hemodilution study, rats were divided into PAN and darbepoetin-treated PAN groups (n ¼ 8 for each). Four milliliter of blood was withdrawn from rats in the group of darbepoetin injection. PAN was induced by a single intravenous injection of PAN (50 mg/kg body weight). Darbepoetin (30 mg/kg) was administered once a week subcutaneously 4 h after hemodilution. On days 7 and 14, urinary protein, blood urea nitrogen, hematocrit, and Hb were measured.
Histology and immunohistochemistry
Kidneys were fixed in 10% neutralized formalin or Methyl Carnoy's solution after removal. They were then processed, embedded in paraffin, and cut into 3 mm thickness sections that were stained with periodic acid-Schiff reagent. For immunohistochemical analysis, sections were incubated with primary antibodies. Anti-desmin antibody, D33, was purchased from DAKO Cytomation (Kyoto, Japan), anti-rat B7-1 from BD Pharmingen (San Diego, CA, USA), anti-EPO-R antibody was purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Immunostaining with the anti-nephrin antibody was performed as reported previously. 50 For B7-1 and EPO-R, sections were processed with Vectastain ABC reagent (Vector Lab, Burlingame, CA, USA).
After 3 h incubation at room temperature with the primary antibody, the sections were incubated with biotinylated secondary antibodies for 1 h, followed by 30-min incubation with horseradish peroxidase-conjugated avidin D (Vector Lab). Color was developed by incubation with diaminobenzidine (Wako Pure Chemical Industries, Tokyo, Japan) and hydrogen peroxide and the sections were counterstained with Mayer's hematoxyline (Wako Pure Chemical Industries, Tokyo, Japan).
For semiquantitative immunohistochemical analysis, 25 glomeruli were selected randomly in each animal and two investigators independently did a blinded immunohistochemical image analysis. The degree of glomerular staining was graded according to the positively stained glomerular area expressed as a percentage of total area: 0, no lesions; 1 þ , 1-25%; 2 þ , 5-50%; 3 þ , 50-75%; 4 þ , 75-100%. An overall staining score per animal was obtained by multiplying each score (0 to 4 þ ) with the percentage of glomeruli displaying the same degree of positive staining and summing these scores.
Electron microscopic analysis
Tissues were fixed with 2.5% glutaraldehyde in phosphate buffer (pH 7.4), postfixed with 1% osmium tetroxide, dehydrated, and embedded in Epon 812 (Okenshoji, Tokyo, Japan). Ultrathin sections were stained with uranyl acetate and lead citrate and were then examined with a Hitachi H7100 electron microscope (Hitachi, Yokohama, Japan).
Culture of temperature-sensitive immortalized podocytes
We employed cultured immortalized rat podocytes. Immortalized rat podocyte cell lines were originally established by Dr Hidetake Kurihara (Juntendo University School of Medicine, Tokyo, Japan). The Cell line, 2DNA1D7, was isolated from decapsulated glomeruli of tsA58 transgenic rats as described previously. 51 Experiments were performed, growth-restricted, conditionally immortalized rat podocytes. Under these conditions, podocytes are fully differentiated and quiescent, resembling the in vivo phenotype. Cells were grown in Dulbecco's modified Eagle's medium/F-12 media containing 10% fetal bovine serum (Gemini Bio-Products, Woodland, CA, USA), penicillin (100 U/ml), streptomycin (100 mg/ml), 0.1% InsulinTrans-Cel-X (Gibco BioChemical, Grand Island, NY, USA). In order to passage cells, podocytes were grown under 'growth permissive' conditions (331C). In order for podocytes to acquire a differentiated and quiescent phenotype, cells were grown under 'restrictive conditions' at 371C in 95% air/5% CO 2 for more than 4 days.
For immunofluorescence, cultured podocytes were grown on chamber slides. Darbepoetin (2 U/ml) was added to the media before addition of PAN at the concentration of 50 mg/ml. After 48 h, cells were fixed and permeabilized with 0.1% Triton X-100. After being washed, cells were labeled with Alexa400-phalloidin.
For immunoblotting, cultured podocytes were passed onto chamber slides and were allowed to adhere and spread. Darbepoetin (2 U/ml) was added to the media before addition of PAN at the concentration of 50 mg/ml. After 48 h, 30 mg of whole extract from cultured podocytes was separated by sodium dodecyl sulfatepolyacrylamide gel electrophoresis under reducing conditions and electrophoretically transferred to nylon membrane. The membrane was incubated with the anti-nephrin or anti-EPO-R antibody. Horseradish peroxidase-conjugated anti-rabbit immunoglobulin G was used as the secondary antibody. Immunoreactive protein was visualized by the chemiluminescence protocol (ECL, Amersham, Arlington Heights, IL, USA).
Reverse transcriptase-PCR analysis
To elucidate expression of EPO-R in the cultured podocytes, 1 mg total RNA was converted to cDNA. cDNA was amplified by two sets of PCR primers that target different regions of rat EPO-R gene. In the first set of primers, oligonecleotides consisting of (forward 5_-TCCGGCATCTCAACAGATTAC-3_ and reverse 5_-AGGGCTTT AAATATGGCCTCA-3_) were synthesized. In the second set of primers, oligonecleotides consisting of (forward 5_-TAGACCCTGC GACTATGGATG-3_ and reverse 5_-ATCGGACACCACAAGGTA CAG-3_) were synthesized. After an initial denaturation step at 951C for 2 min, 30 cycles of PCR amplification (951C, 20 s; 551C, 30 s; 731C, 1 min) were performed. Predicted size of PCR amplification was designed to 200 bp. PCR amplification without cDNA served as a negative control.
TUNEL staining
To detect and quantify apoptotic cells, TUNEL method was performed using In situ Apoptosis Detection Kit (Trevigen, Gaithersburg, MD, USA). Kidneys were fixed in Methyl Carnoy's solution after removal and were embedded in paraffin. Cultured podocytes were fixed with 4% paraformaldehyde. To generate positive controls, samples were treated with TACS-Nuclease before terminal deoxynucleotidyl transferase (TdT) labeling.
Regarding the cultured podocytes, two investigators independently counted apoptotic (TUNEL-positive) cells in 10 randomly selected fields with Â 200 magnification.
Statistical analyses
Differences between the darbepoetin and vehicle-treated groups were evaluated with the unpaired Student's t-test. Nonparametric data, including the histological scores, were analyzed by Mann-Whitney test. Values were considered significant if Po0.05.
